Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19326985 | 1.00 | TSHR (0.52) | TSHRSLC1A1KMT2AMEN1CA12 | |
| SCHEMBL24001173 | 0.84 | TSHR (0.50) | TSHRSLC1A1KMT2AMEN1CA12 | |
| SCHEMBL3584800 | 0.82 | TSHR (0.52) | TSHRSLC1A1KMT2AMEN1CA12 | |
| SCHEMBL3685300 | 0.82 | TSHR (0.52) | TSHRSLC1A1KMT2AMEN1CA12 | |
| SCHEMBL3309517 | 0.82 | TSHR (0.52) | TSHRSLC1A1KMT2AMEN1CA12 | |
| SCHEMBL12951352 | 0.82 | TSHR (0.52) | TSHRSLC1A1KMT2AMEN1CA12 | |
| SCHEMBL18797494 | 0.80 | TSHR (0.50) | TSHRSLC1A1KMT2AMEN1CA12 | |
| SCHEMBL14865411 | 0.80 | TSHR (0.50) | TSHRSLC1A1KMT2AMEN1CA12 | |
| SCHEMBL738598 | 0.80 | TSHR (0.50) | TSHRSLC1A1KMT2AMEN1CA12 | |
| SCHEMBL13880228 | 0.80 | TSHR (0.50) | TSHRSLC1A1KMT2AMEN1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107835818-A | Anthelmintic depsipeptide compounds | 梅里亚股份有限公司 | 2018-03-23 | — | — | CN | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2406251-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1358174-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| EP-0493187-B1 | Process for the stereoselective transformation of a diol to an alcohol | SEPRACOR INC (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5286899-A | Process for the stereoselective transformation of a diol to an alcohol | SEPRACOR, INC. (US) | 1994-02-15 | — | — | US | disclosed |
| US-5189200-A | PROCESS FOR THE STEREOSELECTIVE TRANSFORMATION OF A DIOL TO AN ALCOHOL | SEPRACOR, INC. (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0493187-A1 | Process for the stereoselective transformation of a diol to an alcohol | SEPRACOR, INC. (US) | 1992-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | TSHR 653/4885SLC1A1 625/4885KMT2A 3204/4885 |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | TSHR 3128/4885SLC1A1 4068/4885KMT2A 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.